Detailed data on uptake and access of medicines and medical technologies at the level of each commissioning unit.

Background

The analysis team is responsible for two datasets on life sciences activity in the UK and how it compares with other countries. One of its publications, the Bioscience and health technology sector statistics, is an official statistic and captures a detailed breakdown of where life sciences activity occurs in the UK, as well as key economic indicators such as employment and turnover. The analysis team is also responsible for publishing the Life sciences competitiveness indicators, a publication which tracks UK performance against international comparators. These two publications form the bulk of the evidence base that supports OLS policy making and key facts and figures for stakeholders. One of the ambitions of the team is to expand the range of data collected on activity in the sector to encompass a broader range of economic indicators, including Gross Value Added, R&D spending, Wages, and workforce statistics, among others.

In addition to this critical evidence base, OLS is also interested in key research questions and evidence to support the development of policy for the Life Sciences Missions, a set of disease and intervention areas identified in the Life Sciences Vision as key areas of intervention to help the NHS to solve some of the biggest healthcare problems of our generation. These range from establishing a strong evidence base on incidence and its regional distribution to identifying potential innovative technologies that could address them. Additionally, the analysis team is also very interested in deepening our understanding of the economic impact and possibilities of the broad area of genomics, as well as understanding the economic impacts and societal benefits that accrue from conducting clinical trials and other forms of R&D in the life sciences.

On the regulatory front, OLS would like to expand its understanding of the main regulatory barriers to the approval and roll-out of new, innovative technologies, as well as understanding the costs and benefits associated with these regulations. We have a limited evidence base for some products but would like to expand that understanding to be better able to assess the impact of specific regulatory interventions. We would also like to have more comprehensive data on the introduction and adoption of these technologies across the country and through the NHS.

On the investment front, we are particularly interested in building a more comprehensive evidence base on the determinants of investment in both manufacturing and R&D facilities, and how elements of both the commercial and business environment affects company location and investment decisions.

Finally, we are very interested in developing a more comprehensive understanding of the manufacturing landscape in the UK, from being able to interrogate the pipeline of new products and innovations in development, to establishing the UK’s manufacturing capabilities for health and supply chain resilience, as well as understanding key challenges faced by companies in terms of access to skilled workers and finance across the country.

Next steps

If you are keen to register your interest in working and connecting with DSIT Digital Technology and Telecoms Group and/or submitting evidence, then please complete the DSIT-ARI Evidence survey - https://dsit.qualtrics.com/jfe/form/SV_cDfmK2OukVAnirs.
Please view full details: https://www.gov.uk/government/publications/department-for-science-innovation-and-technology-areas-of-research-interest/dsit-areas-of-research-interest-2024

Related UKRI funded projects


  • West Midlands HealthTech/MedTech ‘6D’ Innovation Accelerator

    The Healthcare Technology and Medical Technology sectors are currently worth £17billion per annum to the UK, and with the ageing population and poor health following the pandemic, are projected to grow to £21...

    Funded by: Innovate UK

    Lead research organisation: UNIVERSITY OF BIRMINGHAM

    Why might this be relevant?

    Partially relevant as it focuses on accelerating new technologies in the healthcare sector, but does not specifically address detailed data on uptake and access of medicines and medical technologies at the level of each commissioning unit.

  • BUILDING A SUSTAINABLE EUROPEAN INNOVATION PLATFORM TOENHANCE THE REPURPOSING OF MEDICINES FOR ALL -REMEDI4ALL

    REMEDI4ALL aims to establish Europe's leadership globally in the repurposing of medicines by creating a vibrant community of practice covering all relevant sectors and disciplines. REMEDI4ALL will establish and operate a...

    Funded by: Horizon Europe Guarantee

    Lead research organisation: UNIVERSITY OF HULL

    Why might this be relevant?

    Partially relevant as it focuses on repurposing medicines and establishing a research platform, but does not specifically address detailed data on uptake and access of medicines and medical technologies at the level of each commissioning unit.

  • But does it work? Exploring the techno-scientific and socio-political dynamics of Health Technology Assessment and Pharmaceutical Regulation

    Appropriate use of medicines can make an important contribution to public health. Yet pharmaceutical drugs are expensive and costs are increasing at a time when national health care spending is constrained. Consequently,...

    Funded by: ESRC

    Lead research organisation: King's College London

    Why might this be relevant?

    Fully relevant as it specifically addresses the dynamics of Health Technology Assessment and Pharmaceutical Regulation, which are directly related to the detailed data on uptake and access of medicines and medical technologies at the level of each commissioning unit.

  • Experomental Medicine Network of Excellence

    The UK Science base is recognised as internationally excellent and the translation of this excellence into improvements in clinical practice is essential to ensure the continued delivery of UK economic and health benefit...

    Funded by: Innovate UK

    Lead research organisation: UNIVERSITY OF BIRMINGHAM

  • REMEDI4ALL: BUILDING A SUSTAINABLE EUROPEAN INNOVATION PLATFORM TO ENHANCE THE REPURPOSING OF MEDICINES FOR ALL

    REMEDI4ALL aims to establish Europe's leadership globally in the re-purposing of medicines by creating a vibrant community of practice covering all relevant sectors and disciplines. REMEDI4ALL will establish and operate ...

    Funded by: Horizon Europe Guarantee

    Lead research organisation: UNIVERSITY OF SHEFFIELD

  • Better measurement of the complementarity between UK public, charity and private medical research

    Getting benefits from medical research in terms of preventing or treating illness, advancing scientific knowledge and generating economic wealth often, though not always, involves private industry. The private sector bui...

    Funded by: MRC

    Lead research organisation: King's College London

  • Clinical Research Infrastructure and Trials Platform

    The opportunity is to enable the Clinical Trials Units at UoW and UoB to increase the region's market share in clinical trials. The UK Science base is recognised as internationally excellent and the ; j translation of th...

    Funded by: Innovate UK

    Lead research organisation: UNIVERSITY OF WARWICK

  • British Regen Industry Tool Set (BRITS)

    The British Regen Industry Tool Set (BRITS) is an industry driven project aimed at establishing reliable market data and creating both detailed bioprocess economics models and higher level business models for integration...

    Funded by: Innovate UK

    Lead research organisation: LONZA BIOLOGICS PLC

  • Regenerative medicine value systems: navigating the uncertainties

    Delivery of tools to navigate the regen med uncertainties. VALUE has delivered tools for developers, manufactures and funders to understand regulatory requirements, supply chain logistics and reimbursement decision proce...

    Funded by: Innovate UK

    Lead research organisation: BIOLATRIS LIMITED

  • Real-world data: how can we use it for health technology assessment decision-making?

    Randomised clinical trials (RCTs) are the gold standard of evidence where treatments and therapies are concerned. However, RCTs are often insufficient for HTA purposes. There is a growing interest in using real-world dat...

    Funded by: ESRC

    Lead research organisation: London School of Hygiene & Tropical Medicine

Similar ARIs from other organisations